disulfiram has been researched along with Melanoma in 12 studies
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The alcohol-abuse deterrent disulfiram (DSF) is shown to have a highly selective toxicity against melanoma in culture, inducing a largely apoptotic response, with much lower toxicity against several other cell lines." | 7.72 | Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. ( Brayton, D; Cen, D; Farmer, PJ; Meyskens, FL; Shahandeh, B, 2004) |
| "Disulfiram (DSF) was identified using a drug screen as one of the several compounds that preferentially decreased proliferation in multiple melanoma subtypes compared with benign melanocytes." | 5.36 | Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. ( Doudican, NA; Morrison, BW; Orlow, SJ; Patel, KR, 2010) |
| "Melanoma is highly resistant to conventional chemotherapy." | 5.31 | Disulfiram induces apoptosis in human melanoma cells: a redox-related process. ( Buckmeier, JA; Cen, D; Gonzalez, RI; Kahlon, RS; Meyskens, FL; Tohidian, NB, 2002) |
| "To investigate: a) whether sub-toxic DSF efficacy can be increased without Cu overload against human melanoma cells with unequal BRAF(V600E) mutant status and Her2-overexpressing SKBR3 breast cancer cells, by increasing H2O2 from exogenous SOD; b) to compare the anti-tumor efficacy of DSF with that of another clinically used copper chelator, tetrathiomolybdate (TTM)." | 3.81 | Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate. ( Calderon-Aparicio, A; Rieber, M; Strasberg-Rieber, M, 2015) |
| "Experimental studies have indicated that disulfiram (Antabuse) has antineoplastic effects against melanoma, breast, and prostate cancer." | 3.80 | Use of disulfiram and risk of cancer: a population-based case-control study. ( Askgaard, G; Friis, S; Hallas, J; Pottegård, A; Thygesen, LC, 2014) |
| "The alcohol-abuse deterrent disulfiram (DSF) is shown to have a highly selective toxicity against melanoma in culture, inducing a largely apoptotic response, with much lower toxicity against several other cell lines." | 3.72 | Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. ( Brayton, D; Cen, D; Farmer, PJ; Meyskens, FL; Shahandeh, B, 2004) |
| "Melanoma is a malignancy of the skin that is resistant to conventional treatment, necessitating the development of effective and safe new therapies." | 1.91 | Subcutaneous Rapid Dissolution Microneedle Patch Integrated with CuO ( Cai, Y; Feng, J; Ni, H; Xu, X; Yu, S; Zhang, J, 2023) |
| "Disulfiram (DSF) was identified using a drug screen as one of the several compounds that preferentially decreased proliferation in multiple melanoma subtypes compared with benign melanocytes." | 1.36 | Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. ( Doudican, NA; Morrison, BW; Orlow, SJ; Patel, KR, 2010) |
| "Melanoma is highly resistant to conventional chemotherapy." | 1.31 | Disulfiram induces apoptosis in human melanoma cells: a redox-related process. ( Buckmeier, JA; Cen, D; Gonzalez, RI; Kahlon, RS; Meyskens, FL; Tohidian, NB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, C | 1 |
| Zhou, S | 1 |
| Chen, C | 1 |
| Zhu, L | 1 |
| Li, S | 1 |
| Song, Z | 1 |
| Liang, J | 1 |
| Tang, C | 1 |
| Xu, N | 1 |
| Liu, T | 1 |
| Liu, S | 1 |
| Yu, S | 1 |
| Ni, H | 1 |
| Xu, X | 1 |
| Cai, Y | 1 |
| Feng, J | 1 |
| Zhang, J | 1 |
| Askgaard, G | 1 |
| Friis, S | 1 |
| Hallas, J | 1 |
| Thygesen, LC | 1 |
| Pottegård, A | 1 |
| Cavalier, MC | 1 |
| Pierce, AD | 1 |
| Wilder, PT | 1 |
| Alasady, MJ | 1 |
| Hartman, KG | 1 |
| Neau, DB | 1 |
| Foley, TL | 1 |
| Jadhav, A | 1 |
| Maloney, DJ | 1 |
| Simeonov, A | 1 |
| Toth, EA | 1 |
| Weber, DJ | 1 |
| Calderon-Aparicio, A | 1 |
| Strasberg-Rieber, M | 1 |
| Rieber, M | 1 |
| Fernandez Del Ama, L | 1 |
| Jones, M | 1 |
| Walker, P | 1 |
| Chapman, A | 1 |
| Braun, JA | 1 |
| Mohr, J | 1 |
| Hurlstone, AF | 1 |
| Morrison, BW | 1 |
| Doudican, NA | 1 |
| Patel, KR | 1 |
| Orlow, SJ | 1 |
| Trapp, V | 1 |
| Lee, K | 1 |
| Doñate, F | 1 |
| Mazar, AP | 1 |
| Fruehauf, JP | 1 |
| Cen, D | 2 |
| Gonzalez, RI | 1 |
| Buckmeier, JA | 1 |
| Kahlon, RS | 1 |
| Tohidian, NB | 1 |
| Meyskens, FL | 2 |
| Brar, SS | 1 |
| Grigg, C | 1 |
| Wilson, KS | 1 |
| Holder, WD | 1 |
| Dreau, D | 1 |
| Austin, C | 1 |
| Foster, M | 1 |
| Ghio, AJ | 1 |
| Whorton, AR | 1 |
| Stowell, GW | 1 |
| Whittall, LB | 1 |
| Whittle, RR | 1 |
| White, DP | 1 |
| Kennedy, TP | 1 |
| Brayton, D | 1 |
| Shahandeh, B | 1 |
| Farmer, PJ | 1 |
| Thibaut, S | 1 |
| Bourré, L | 1 |
| Hernot, D | 1 |
| Rousset, N | 1 |
| Lajat, Y | 1 |
| Patrice, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer[NCT03323346] | Phase 2 | 150 participants (Anticipated) | Interventional | 2017-09-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 other studies available for disulfiram and Melanoma
| Article | Year |
|---|---|
DDTC-Cu(I) based metal-organic framework (MOF) for targeted melanoma therapy by inducing SLC7A11/GPX4-mediated ferroptosis.
Topics: Alcoholism; Amino Acid Transport System y+; Animals; Cell Line, Tumor; Copper; Disulfiram; Ditiocarb | 2023 |
DDTC-Cu(I) based metal-organic framework (MOF) for targeted melanoma therapy by inducing SLC7A11/GPX4-mediated ferroptosis.
Topics: Alcoholism; Amino Acid Transport System y+; Animals; Cell Line, Tumor; Copper; Disulfiram; Ditiocarb | 2023 |
Subcutaneous Rapid Dissolution Microneedle Patch Integrated with CuO
Topics: Disulfiram; Humans; Hydrogen Peroxide; Melanoma; Micelles; Photothermal Therapy; Povidone | 2023 |
Subcutaneous Rapid Dissolution Microneedle Patch Integrated with CuO
Topics: Disulfiram; Humans; Hydrogen Peroxide; Melanoma; Micelles; Photothermal Therapy; Povidone | 2023 |
Use of disulfiram and risk of cancer: a population-based case-control study.
Topics: Aged; Alcohol Deterrents; Breast Neoplasms; Case-Control Studies; Denmark; Disulfiram; Female; Human | 2014 |
Use of disulfiram and risk of cancer: a population-based case-control study.
Topics: Aged; Alcohol Deterrents; Breast Neoplasms; Case-Control Studies; Denmark; Disulfiram; Female; Human | 2014 |
Covalent small molecule inhibitors of Ca(2+)-bound S100B.
Topics: Animals; Benzophenanthridines; Benzoquinones; Binding Sites; Calcium; Cations, Divalent; Cattle; Cel | 2014 |
Covalent small molecule inhibitors of Ca(2+)-bound S100B.
Topics: Animals; Benzophenanthridines; Benzoquinones; Binding Sites; Calcium; Cations, Divalent; Cattle; Cel | 2014 |
Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.
Topics: Acetylcysteine; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell S | 2015 |
Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.
Topics: Acetylcysteine; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell S | 2015 |
Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics.
Topics: Abietanes; Animals; Animals, Genetically Modified; Apoptosis; Benzamides; Cell Line, Tumor; Disease | 2016 |
Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics.
Topics: Abietanes; Animals; Animals, Genetically Modified; Apoptosis; Benzamides; Cell Line, Tumor; Disease | 2016 |
Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma.
Topics: Apoptosis; Cell Growth Processes; Cell Line, Tumor; Copper; Copper Sulfate; Disulfiram; Humans; Mela | 2010 |
Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma.
Topics: Apoptosis; Cell Growth Processes; Cell Line, Tumor; Copper; Copper Sulfate; Disulfiram; Humans; Mela | 2010 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, T | 2009 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, T | 2009 |
Disulfiram induces apoptosis in human melanoma cells: a redox-related process.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Buthionine Sulfoximine; Cell Division; Disulfiram; Enzym | 2002 |
Disulfiram induces apoptosis in human melanoma cells: a redox-related process.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Buthionine Sulfoximine; Cell Division; Disulfiram; Enzym | 2002 |
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Copper; Cyclic AMP Response El | 2004 |
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Copper; Cyclic AMP Response El | 2004 |
Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells.
Topics: Apoptosis; Cell Line, Tumor; Copper; Disulfiram; Humans; Melanoma; Phenanthrolines | 2004 |
Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells.
Topics: Apoptosis; Cell Line, Tumor; Copper; Disulfiram; Humans; Melanoma; Phenanthrolines | 2004 |
Effects of BAPTA-AM, Forskolin, DSF and Z.VAD.fmk on PDT-induced apoptosis and m-THPC phototoxicity on B16 cells.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Cell Survival; Chelating Agents; Colforsin; Cys | 2002 |
Effects of BAPTA-AM, Forskolin, DSF and Z.VAD.fmk on PDT-induced apoptosis and m-THPC phototoxicity on B16 cells.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Cell Survival; Chelating Agents; Colforsin; Cys | 2002 |